Webinar | March 6, 2018

Is Your Clinical Supply Playbook Ready for Phase II and Beyond?

Source: Catalent

Advancing promising investigational medicines to Phase II and beyond for the first time is an exciting time for clinical sponsors with young pipelines – and an eye opening one as well. Experience has shown that certain study characteristics can act as useful leading indicators of future clinical supply challenges. By examining these factors, clinical sponsors can take a proactive rather than reactive approach to clinical supplies.

Learn more about:

  • How clinical supply & the supply chain change from Ph. I, Ph. II & Ph. III.
  • Which study characteristics significantly contribute to clinical supply complexity.
  • How to build an informed and proactive clinical supply strategy.